Nuhrenberg TG, et al. - Authors compared the efficacy and safety of bivalirudin vs heparin in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). It was determined that no significant differences were seen for MACE, death, myocardial infarction, and stent thrombosis between the two treatments. Even after stratification by use of glycoprotein inhibitors (GPI), the results were comparable. Data revealed that patients treated with bivalirudin tended to have less major bleeding, but bivalirudin was not linked with decreased bleeding when use of GPI was balanced.